share_log

Piper Sandler Maintains Overweight on Altimmune, Lowers Price Target to $25

Benzinga Real-time News ·  May 18, 2022 06:44

Piper Sandler analyst Yasmeen Rahimi maintains Altimmune (NASDAQ:ALT) with a Overweight and lowers the price target from $34 to $25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment